Gates Foundation grants biotech firm Aeras $220 million over 5 years to develop TB vaccines

NewsGuard 100/100 Score

The Bill & Melinda Gates Foundation is "to give $220 million over five years to the non-profit biotech firm Aeras to develop vaccines to fight tuberculosis [TB], a company statement said Thursday," Agence France-Presse reports (3/15). The "grant will allow Aeras to advance several vaccine candidates into pivotal large-scale efficacy trials in South Africa and elsewhere," South Africa's Health-e writes (Thom, 3/15). According to AFP, Aeras "has developed six possible TB vaccines that are being tested across Africa, Asia, Europe and America" (3/15).

"Aeras estimates a total of $400-500 million will be needed over the next five years to fund activities," Health-e writes, noting, "The Gates grant provides approximately half of the estimated cost of meeting 2012 to 2016 milestone targets" (3/15). "Trevor Mundel, president of the global health program at the Bill & Melinda Gates Foundation, said the development of successful vaccines 'would be the single greatest advance in the global fight against TB,'" AFP writes (3/15).


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    New classification of tuberculosis aims to improve focus on the early stages of disease